TargetMol

2,4,6-Tribromo-3-methylphenol

Product Code:
 
TAR-T21286
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T21286-100mg100mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21286-500mg500mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
2,4,6-Tribromo-m-cresol is a bioactive chemical.
CAS:
4619-74-3
Molecular Weight:
344.83
Purity:
0.98
SMILES:
BrC=1C=C(Br)C(=C(Br)C1O)C

References

Hwang BH, Jung KA, Ong A, Ahn HS, Moon SH, Lee SC. Patellar Impingement on Tibial Polyethylene after Primary Total Knee Arthroplasty without Patellar Resurfacing. J Knee Surg. 2019 Aug 30. doi: 10.1055/s-0039-1695704. [Epub ahead of print] PubMed PMID: 31470453. Deren ME, Pannu TS, Villa JM, Firtha M, Riesgo AM, Higuera CA. Meta-analysis Comparing Allograft to Synthetic Reconstruction for Extensor Mechanism Disruption after Total Knee Arthroplasty. J Knee Surg. 2019 Aug 30. doi: 10.1055/s-0039-1696656. [Epub ahead of print] PubMed PMID: 31470450. Franchi F, Rollini F, Garcia E, Rivas Rios J, Rivas A, Agarwal M, Kureti M, Nagaraju D, Wali M, Briceno M, Moon JY, Kairouz V, Yaranov D, Been L, Suryadevara S, Soffer D, Zenni MM, Bass TA, Angiolillo DJ. Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study. Thromb Haemost. 2019 Aug 30. doi: 10.1055/s-0039-1695772. [Epub ahead of print] PubMed PMID: 31470444. Fanikos J, Murwin D, Gruenenfelder F, Tartakovsky I, Fran?a LR, Reilly PA, Kermer P, Wowern FV, Lane DA, Butcher K. Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program. Thromb Haemost. 2019 Aug 30. doi: 10.1055/s-0039-1695771. [Epub ahead of print] PubMed PMID: 31470445.